drugset / Trial / NCT02821819

Random-start Ovarian Stimulation in Egg-donors (ROSE)

NCT02821819

Phase 4 Terminated 15 enrolled Instituto Bernabeu
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this prospective single-center study is to evaluate the laboratory outcome after random start ovarian stimulation in oocyte donors. The study will be performed in egg-donors but this type of treatment has the potential to be implemented in general infertility population.

Timeline

Start
2017-01-10
Primary completion
2018-01-12
Completion
2018-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bravelle Unknown 150 iu
Subject Bravelle Unknown 225 iu
Background Cetrorelix Other / unclassified 0.25 mg
Background Triptorelin Other / unclassified 0.2 mg

Indications